PharmiWeb

Corteria Pharmaceuticals initiates Phase 2 trial in heart failure and Phase 1 trial in obesity with its first-in-class CRF2 agonists

CRAFT-WHF Phase 2 trial of COR-1167 initiated in patients with worsening heart failure Phase 1 trial of COR-1389 ongoing in subjects with obesity Paris, France, July 21, 2025 – Corteria ...
Seeking Alpha

Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts

Tenax Therapeutics (TENX) is in a very good position as far as its drug development plan goes for its drug levosimendan. That's because it is already in the process of running the ongoing phase 3 ...
Seeking Alpha

Merck’s WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint in Phase 2 CADENCE Study in Adults With Combined Post- and Precapillary Pulmonary Hypertension (CpcPH) due to ...

WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the primary endpoint of pulmonary vascular resistance (PVR) compared to placebo, improving the ability of ...
FierceBiotech

Novartis' serelaxin misses endpoint in heart failure phase 3

Novartis’ phase 3 trial of serelaxin in acute heart failure has missed its primary endpoint. The Swiss pharma saw the 6,600-patient trial as a way to bounce back from FDA’s 2014 rejection, but instead ...